Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DUPILUMAB Cause Dermatitis exfoliative generalised? 162 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 162 reports of Dermatitis exfoliative generalised have been filed in association with DUPILUMAB (Dupixent). This represents 0.0% of all adverse event reports for DUPILUMAB.

162
Reports of Dermatitis exfoliative generalised with DUPILUMAB
0.0%
of all DUPILUMAB reports
5
Deaths
35
Hospitalizations

How Dangerous Is Dermatitis exfoliative generalised From DUPILUMAB?

Of the 162 reports, 5 (3.1%) resulted in death, 35 (21.6%) required hospitalization, and 1 (0.6%) were considered life-threatening.

Is Dermatitis exfoliative generalised Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DUPILUMAB. However, 162 reports have been filed with the FAERS database.

What Other Side Effects Does DUPILUMAB Cause?

Pruritus (44,279) Dermatitis atopic (33,670) Product use in unapproved indication (33,452) Rash (30,895) Injection site pain (27,799) Drug ineffective (23,712) Dry skin (20,239) Eczema (20,020) Product dose omission issue (18,189) Condition aggravated (16,459)

What Other Drugs Cause Dermatitis exfoliative generalised?

ALLOPURINOL (192) METHOTREXATE (151) SULFAMETHOXAZOLE\TRIMETHOPRIM (140) AMOXICILLIN (122) ADALIMUMAB (113) PANTOPRAZOLE (105) SECUKINUMAB (96) VANCOMYCIN (92) AMLODIPINE (91) LENALIDOMIDE (89)

Which DUPILUMAB Alternatives Have Lower Dermatitis exfoliative generalised Risk?

DUPILUMAB vs DURAGESIC DUPILUMAB vs DUROGESIC DUPILUMAB vs DUROTEP MT DUPILUMAB vs DURVALUMAB DUPILUMAB vs DUTASTERIDE

Related Pages

DUPILUMAB Full Profile All Dermatitis exfoliative generalised Reports All Drugs Causing Dermatitis exfoliative generalised DUPILUMAB Demographics